𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Recombinant interferon alpha therapy in elderly patients with chronic hepatitis C without cirrhosis

✍ Scribed by M. Russello; E. Vasquez; F. Fraggetta; M. Zammataro

Publisher
Elsevier Science
Year
1996
Tongue
English
Weight
294 KB
Volume
22
Category
Article
ISSN
0167-4943

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Treatment of chronic hepatitis C with ci
Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon-alpha
✍ Margarita Pardo; Inmaculada Castillo; Sonia Navas; Dr. Vicente CarreΓ±o πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 525 KB

Interferon therapy in cirrhotic patients with hepatitis C virus infection is not efficient. In an at- tempt t o improve the response rate, a pilot study using recombinant human granulocyte colonystimulating factor (rhG-CSF) alone, and in combination with recombinant interferon-alpha (rlFN), was carr

Therapy of chronic hepatitis b with reco
Therapy of chronic hepatitis b with recombinant human alpha and gamma interferon
✍ Adrian M. Di Bisceglie; Vinod K. Rustgi; Chris Kassianides; Mauricio Lisker-Melm πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 584 KB

Eight patients with chronic hepatitis B entered a pilot study of gamma interferon and alpha interferon in combination. Gamma interferon alone had minimal inhibitory effects on serum levels of hepatitis B virus as monitored by serum HBV DNA and DNA-polymerase activity. The drug also gave troublesome

Prolonged-interferon therapy reduces hep
Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C
✍ Yasuji Arase; Kenji Ikeda; Fumitaka Suzuki; Yoshiyuki Suzuki; Masahiro Kobayashi πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 129 KB

## Abstract The aim of this study was to elucidate the reduction of hepatocarcinogenesis by prolonged interferon (IFN) monotherapy in aged chronic hepatitis C patients. Inclusion criteria were biopsy‐proven chronic hepatitis or liver cirrhosis, 60 years and over, elevated serum aminotransferase and